drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified autologous T cells)
drug_description
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor; administered intraventricularly as an adjunct/rescue dose to deplete CD19-positive B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intraventricular
drug_mechanism_of_action
Autologous T cells are gene‑modified to express a chimeric antigen receptor specific for CD19. Upon binding CD19 on B cells, the CAR provides activation and costimulatory signals that trigger T‑cell cytotoxicity (perforin/granzyme) and cytokine release, leading to targeted depletion of CD19‑positive B cells; in this study, administered intraventricularly as an adjunct/rescue dose.
drug_name
CD19 CAR T cells
nct_id_drug_ref
NCT05544526